Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS
TLSA•Phase 2a ALS trial launched in Healey ALS MyMatch program
Tiziana Life Sciences announced a Phase 2a BANYAN trial of intranasal foralumab in ALS within the Healey ALS MyMatch program.
Trial rationale and design were presented in a poster session at ALS Nexus 2026; no clinical results were reported.
The study is designed to assess safety, immune-modulation biomarkers, neuroinflammation signals, and early signs of clinical benefit versus placebo.
The trial will use a randomized 3:1 foralumab-to-placebo design across NEALS sites, with enrollment timing and the site list to be detailed later.
